EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 9
Issue: 11
145-154
Year: 2022

GOOD REGULATORY PRACTICE: A PROPOSAL FOR A QUALITY SYSTEM.

Abhijit Sasmal*[1], Koustav Chowdhury[2] and Tania Sadhu[3]

[1,2,3]Research Scholar, Department of Pharmacology, Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka.

***Corresponding Author: Abhijit Sasmal**
Research Scholar, Department of Pharmacology, Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka.

Article Received on 01/09/2022 **Article Revised on 22/09/2022** **Article Accepted on 13/10/2022**

ABSTRACT
A pharmaceutical company's Drug Regulatory Affairs (DRA) department is crucial. In order to speed up the development and delivery of safety and efficacy in pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines, healthcare products to people all over the world, it is concerned with the lifecycle of healthcare products. It provides strategic, tactical and operational direction and support for working within regulations. Professionals in regulatory affairs (RA) work for the pharmaceutical sector, the government, academic research institutes, and clinical facilities. In order to meet the present demands of companies for the global competitiveness, regulatory affairs specialists are required because the pharmaceutical sector in India is expanding extremely quickly. The international regulatory authorities and the pharmaceutical industry are connected through regulatory affairs specialists. A regulatory affair is a relatively young profession that emerged from governments' efforts to protect public health. Large, complicated applications are produced as a result of the substantial paperwork and data that must be included in these submissions. The Pharmaceutical Inspection Cooperation Scheme (PIC/S) was established today to promote a GMP that is universally recognised. It consists of 35 member nations, 11 applicant countries, and 4 international institutions.

KEYWORDS: Drug regulatory affairs, Regulatory agencies, FDA, Pharmaceutical Inspection Cooperation Scheme (PIC/S), GMP, USFDA, CDSCO.

INTRODUCTION
The pharmaceutical industry's quality has grown to be a major issue. A greater understanding of the importance of the quality of pharmaceutical goods has emerged since the world came together to standardize its practices and guidelines and the FDA's current good manufacturing practices (cGMP) for the 21st century was introduced.[1] The emergence of several definitions describing precisely what the quality of the medication should be serves as a representation of this awareness.[2] Numerous articles were produced to highlight the unique characteristics of the connection between patients and medicine as a product.[1] The international pharmaceutical federation (FIP)[3] and the international federation of pharmaceutical manufacturer associations (IFPMA) jointly issued a statement in 1999 highlighting the importance of governments in ensuring the safety of pharmaceuticals in order to protect patients, noting that the pharmaceutical industry has been one of the most stringently regulated sectors for more than 50 years.[1] The FDA launched a project in 2002 to address cGMP for the twenty-first century.[1] This approach includes examining the industrial and regulatory processes for ensuring medication quality from fresh angles.[4] 102 articles that focus on conceptual concerns, methodological issues, or the implementation of various methods and/or guidelines utilized in the pharmaceutical industries were found in a study of the literature on the quality in the pharmaceutical sector. Several themes were found after analyzing the content of various sources. The two goals of the literature study are to create a manual for other people to utilize and to examine the quality standards and organizational procedures in the pharmaceutical sector. This type of study helps to synthesize prior research and can assist present and future researchers, practitioners, and practitioners who use the appropriate guideline or practice in developing their methodological judgments in modernizing the industry. This article discussed some of the challenges surrounding what makes pharmaceutical quality so unique before identifying several quality factors.[5,6] The topics uncovered by the research and how they developed come next. The discussion of management implications concludes.

The study of regulatory affairs is a very broad area. A professional need several years to fully understand just a small portion of this area. Companies reassure regulatory bodies that the products being sold fulfil all regulatory requirements for quality, purity, safety, and efficacy

through the dynamics of RA. When a producer of a medication, gadget, or biological product export their product to many nations, the complexity of regulatory affairs is multiplied by several orders of magnitude.

RA involves complex dynamics-

- Multi-dimensional
- Knowledge in science and technology
- Prolific communication skill
- Deal with people with diverse backgrounds, skills cultures, and personalities
- Deal with conflicting loyalties, motivations, social and ethical responsibilities.[7]

The modern pharmaceutical industry is well-organized, methodical, and complying with worldwide regulatory requirements for producing medical equipment, traditional herbal medicines, cosmetics, and chemical and biological medications for human and veterinary consumption. Blood and its derivatives are produced under strict GMP guidelines, and traditional herbal medicines, cosmetics, food, and dietary items are now manufactured under strict supervision, as opposed to how they were done a century ago. The existing well-defined regulated regulatory framework is the result of specific conditions that each regulatory system has to deal with. As a result, safe, effective, and high-quality medications are now manufactured and marketed in a methodical manner. The thalidomide, vaccination, and sulfanilamide elixir catastrophes of the 1950s led to a significant expansion of laws governing the quality, safety, and effectiveness of pharmaceutical goods. Additionally, this has led to tougher standards for Good Manufacturing Practices (GMP) and Marketing Authorization (MA). Making ensuring that all information about medications has been accurately presented to the patient, including labelling, is one of the regulatory authority's most important tasks. Any violations to regulatory activity can result in the product being recalled, costing several millions of dollars in addition to a little error.[8]

As the pharmaceutical industries around the world progress toward becoming more and more competitive, these sectors are realizing that the real struggle for survival lies in carrying out the work while understanding the rules related to the various activities carried out to provide reassurance that the process is governed. The pharmaceutical industry, one of the most heavily regulated, is in greater demand than ever of individuals who are able to manage difficulties relating to regulatory affairs in a thorough manner.[7] Regulatory affairs, often known as government affairs, is a career inside regulated industries, including healthcare, finance, energy, and pharmaceuticals. Within the healthcare industry, a regulatory matter also has a very precise definition (Pharmaceutical, medical devices, Biologics, and functional foods.) Most businesses have specialized regulatory affairs (RA) departments, whether they are large global pharmaceutical enterprises or tiny, creative biotechnology companies. The effectiveness of a regulatory strategy is less reliant on the regulations than it is on how they are interpreted, put into practice, and communicated to internal stakeholders and external stakeholders. Figure 1 depicts the many roles played by the DRA department.



Figure 1: Various role of DRA department.

Pharma regulatory affairs specialists are crucial in ensuring that all pharmaceutical goods adhere to rules governing the sector.[9] Pharma regulatory affairs professionals ensure that all operations and products comply with regulations during licensing and marketing stages as well as during the initial application phase for new or generic drugs. They also use their knowledge of the business, legal, and pharmaceutical industries to assess whether regulations are being followed. In many cases, they serve as a liaison between pharmaceutical

companies and regulatory agencies like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Jobs in regulatory affairs are often found in the pharmaceutical, chemical, biotechnology, medical device, and cosmetic sectors in the UK and abroad. Roles were also made available for persons interested in the subject by organizations like the FDA. A growing number of roles in biotech regulatory affairs are becoming available as biotechnology plays a larger role in medication research and the pharmaceutical sector. Due to the constantly evolving technologies employed, inspection of biotechnology facilities demands a high degree of technical expertise.[10] The numerous significant regulatory agencies of different countries are listed in Table 1.

Table 1: Various Major Regulatory Authorities of Different Country.

Country	Regulatory Authority
India	Central Drug Standard Control Organization (CDSCO) Drug Controller General of India (DCGI)
US	United States Food & Drugs Administration
UK	Medicine & Healthcare products Regulatory Agency (MHRA)
Australia	Therapeutic Goods Administration (TGA)
Japan	Japanese Ministry of Health, Labour & Welfare (MHLW)
Canada	Health Canada
Brazil	Agência Nacional de Vigilância Sanitária
South Africa	Medicines Control Council
Europe	European Directorate for Quality of Medicines (EDQM) European Medicines Evaluation Agencies (EMEA)

The individual is in charge of being aware of the legal requirements for approving new items. They are aware of the promises the business has made to the regulatory bodies from which the product has received approval.[11] Additionally, they send the agencies annual reports and supplements. Instead of the local district offices of the FDA, regulatory affairs frequently connect with one of the centers (such as the Centre for Drug Evaluation and Research) at the FDA headquarters. Regulatory Affairs must comprehend and assess changes to medication manufacturing and testing operations to decide whether and when the FDA must be notified.[12] In order to oversee the safety and efficacy of goods in a variety of industries, including pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics, and complementary therapies, governments have created the relatively young profession of regulatory affairs.**[13]** The businesses in charge of the development, testing, production, and marketing of these items also want to make sure that they deliver goods that are secure and meaningfully advance the health and welfare of the general population. Their regulatory affairs departments must be aware of the regulatory requirements in all the company's export markets.**[14]** The regulatory affairs department will participate in the development of the product marketing concepts and is typically required to approve packaging and advertising before it is used commercially. Despite recent international efforts to harmonies standards, the laws established by various nations present an additional complexity. In order to create effective and affordable research and build programmes whose outcomes may be applied as broadly as possible, significant attention must be taken. Professionals in regulatory affairs are regularly asked for guidance on these issues due to their in-depth understanding of the rules and regulations.[15]

Regulatory Affairs Education

The individual involved in regulatory affairs has to be knowledgeable about all regulations, rules, and documentation. He ought to be well-versed on a certain regulatory document that has been written. These individuals serve as the company's main point of contact with international regulatory organizations like the European Union of Drug Regulatory Affairs and the United States Food and Drug Administration (USFDA) (EUDRA).**[16]** Several groups, like the Regulatory Affairs Professional Society (RAPS), the Drug Information Association (DIA), the Food and Drug Law Institute (FDLI), and international groups like the European Society of Regulatory Affairs, play important roles in disseminating pertinent data.**[17]** In general, the curriculum consists of an introductory foundation that describes the complicated process of health care product research, development, and regulatory control. The subject is covered in both full-time and part-time courses.[18] Full-time courses are designed for professionals who want to create a career in regulatory affairs, whilst part-time courses are appropriate for professionals who will only infrequently encounter these words.[19]

Recent advancement

Recently, the Govt. of India has constituted a few autonomous bodies to gauge the standards of profession of Pharmacy & grade the colleges accordingly so that the students, parents, employers and funding agencies have a valid and reliable rating of the various pharmacy colleges in the country.[20]

These are:

1. National Board of Accreditation (NBA) under the aegis of All India Council for Technical Education.
2. National Assessment and Accreditation Council (NAAC) by the University Grants Commission.

The Drug Regulatory Affairs Professional

In order to fulfil regulatory standards and enable a favorable review of efficacy and safety in the shortest amount of time feasible, it is crucial that the pharmaceutical research and development process—which takes several years—be handled properly from beginning to conclusion.[21] Every stage of this process, from formulating regulatory strategies after the discovery of a new chemical entity to organizing post-marketing operations, involves the drug regulatory affairs (DRA) professional.

The primary duty of a DRA professional working for a pharmaceutical business is to ensure that drug submissions are approved by the Health Therapeutic Product Program (TPP) and that experimental and marketed pharmaceuticals are in conformity with TPP Guidelines/Policies and the Food and Drug Act.[22]

The DRA professional for this role must have a strong scientific background (B.sc, M.sc, Ph.D., M.D., B. Pharm, M. Pharm, or Pham. D.) and thorough understanding of both Indian and international legislation.[23] It is a significant challenge for the DRA professional to stay on top of policy changes and determine how these changes affect the approval process because the regulatory environment is rapidly evolving toward global harmonization (Several ICH guidelines have now been adopted by TPP) and mutual recognition between different health authorities across the world. As a result, during the past ten years, DRA has become more crucial in the creation and approval of novel medications.[24]

Whether a submission is made to the TPP for the purpose of conducting a clinical trial (Investigational New Drug Submission, or IND), for receiving approval to market a new drug (New Drug Submission, or NDS), for adding a new indication or dosage form to an already-marketed drug (Supplemental NDS, or S/NDS), or for maintaining the regulatory status of an already-marketed drug, the preparation of the submission necessitates close teamwork across multiple disciplines.[25] To gather all required documents in accordance with current TPP regulations, the DRA professional must actively participate in conversations and organize team activities. After obtaining all required documentation, they must check it for accuracy and completeness. As a result, the successful DRA professional must have "team player" interpersonal and organizational abilities as well as be thorough and detail oriented.[26]

The range of duties is broad and might differ greatly depending on how the pharmaceutical firm is organized. Some DRA professionals may just be responsible for pharmacovigilance tasks or information representation in electronic form (electronic submission).[27] The primary point of contact between the sponsor and the TPP, however, is the DRA professional. The person serving in this position has to be an outstanding writer, communicator, and negotiator. In addition to negotiating the most advantageous labelling (Product Monograph) compatible with the sponsor's commercial objectives, this is done to guarantee that any requests or criticisms made throughout the submission's evaluation process are swiftly and satisfactorily addressed.[28]

Given the expanding technical innovations of today, proficiency in a variety of computer applications is necessary to successfully complete the work requirements. The discipline of drug regulatory affairs (DRA) is one that covers both the scientific and legal facets of drug research. DRA specialists are devoted persons who take satisfaction in their commitment to raising people's health and quality of life.[29]



Spectrum of Regulatory Analysis

Responsibility of Regular Affairs Professional's

The responsibility of the regulatory affairs specialist is to stay abreast of the constantly evolving legal framework in every area where the firm plans to sell its goods. Additionally, they gather, compile, and assess the scientific data that their research and development

colleagues are producing. They also provide advice on the limitations and needs of law and science.[30] They are in charge of submitting registration documentation to regulatory bodies and managing any following talks required to uphold the related products' marketing license. From the very beginning of a product's development, they provide strategic and technical guidance at the highest levels of their organizations, significantly contributing both economically and scientifically to the success of a development programme and the organization as a whole.[31]

A new pharmaceutical product may take up to 15 years to develop and commercialize, during which time several issues may occur due to shifting regulatory environments and scientific research processes.[32] Professionals in regulatory affairs (RA) assist the business in avoiding issues brought on by improper scientific reasoning, poorly maintained records, or poor data presentation. Restrictions on the claims that can be made for the product on labelling or in advertising are also applied in the majority of product categories where regulatory limitations are required.[33]

List of responsibilities of Regulatory Affairs Department

a. Keep in touch with international legislation, guidelines, and customer practices
b. Keep up to the date with a company's product range
c. Ensure that a company's product comply with the current regulations.
d. The Regulatory Affairs professional's job is to keep track of the ever-changing legislation in all the region in which the company wishes to distribute its products. They also advise on the legal and scientific restrains and requirements, and collect, collate, and evaluate the scientific data that their research and development colleagues and generating. **[34]**
e. Formulate regulatory strategy for all appropriate regulatory submissions for domestic, international and/ or contract projects.
f. Coordinate, prepare and review all appropriate documents for example dossier and submit them to regulatory authorities within a specified time frame in conjugation with the organization.
g. Prepare and review of SOPs related to RA. Review of BMR, MFR, Change control and other relevant documents.**[35]**
h. Monitor the progress of all registration submission.
i. Maintain approved applications and the record of registration fees paid against submission of DMF's and other documents.
j. Respond to queries as they arise and ensure that registration/approval are granted without delay.**[36]**
k. Import training to R&D, pilot plant, ADI and RA. Team members on current regulatory requirements.
l. Advising their companies on the regulatory aspects and climate that would affect proposed activities. i.e., describing the "regulatory climate" around issues such as the promotion of prescription drugs and Sarbanes – Oxley compliance.
m. Mange review audit reports and compliance, regulatory and customer inspections. **[37]**
n. Regulatory Affairs professionals help the company avoid problems caused by badly kept records, inappropriate scientific thinking or poor presentation of data. On most product areas where regulatory requirements are imposed, restrictions are also placed upon the claims which can be made for the product on labelling or in advertising.
o. Have a duty to provide physicians and other healthcare professionals with accurate and complete information about the quality, safety and effectiveness of the product.

Makes a Good Regulatory affairs Professional

The majority of regulatory professionals has degrees in a scientific field, most frequently in the biological sciences or pharmacy, however degrees in biotechnology are becoming more and more useful. Some people choose for a second legal qualification. It is crucial to have the capacity to work with data from a variety of scientific disciplines and to swiftly pick up new ideas and complicated technical facts. It takes extensive knowledge of both legal and scientific concerns to analyze problems and present written and oral evidence to a panel of specialists, including scientists, pharmacists, physicians, and lawyers who manage government bodies.[38]

When presenting and carrying out the strategy and tactics necessary to gain marketing clearance in a way that will please the authorities and serve the best possible case is to be submitted to the authorities for the firm, a high degree of sensitivity is required. To enable the authorities to reach a reasonable and legitimate judgement regarding the safety, effectiveness, and quality of the product under application, it must be done without distorting the facts. Regulatory professionals must constantly use a great deal of discretion while doing their duties. Integrity and the capacity to foster confidence and trust are desirable qualities. The difficult targets they are set aid to be achieved with project management abilities. **[39]** They may participate in multidisciplinary teams and, if required, take the lead. They have the ability to work under pressure and push others to do the same.

Need of regulatory affairs in the pharmacy curriculum

One of the most tightly regulated sectors in the nation is the research and development of pharmaceutical, biotechnology, and medical devices. In order to meet the present demands of companies for the global competitiveness, regulatory affairs specialists are required because the pharmaceutical sector in India is expanding extremely quickly.

The international regulatory authorities and the pharmaceutical industry are connected through regulatory affairs specialists. They must be well-versed in the laws, rules, directives, and regulations of the

regulating bodies. To better prepare students for careers in the pharmaceutical industry, it is becoming increasingly necessary to include the most recent innovations in the conventional curriculum of pharmacy institutions. The purpose of this article is to address the need for regulatory education, learning resources, courses that are offered, course material, and employment prospects in regulatory affairs.[40]

The pharmaceutical industries around the world are realizing that the real struggle for survival lies in carrying out the work by understanding the guidelines related to various activities carried out to provide an assurance that the process is under regulation as they move forward toward becoming more and more competitive. Being one of the heavily regulated businesses, the pharmaceutical industry is equipped to handle regulatory affairs difficulties in a thorough manner.[41]

Drug Approval Process in India

The Indian Parliament passed the Drug and Cosmetic Act 1940 and Rules 1945 to control the importation, production, distribution, and sale of medications and cosmetics.

The standards and criteria for clinical trials are included in Schedule Y, which was updated in 2005 to bring it into compliance with generally accepted practise.

The Drugs Controller General (DCGI) office and the Central Drugs Standard Control Organization (CDSCO) were formed.[42]

The Drug and Cosmetics Rules of 1945 were amended by the Indian government to include Schedule Y in 1988. A firm in India must submit Form 44 together with the information required under Schedule Y of the Drugs and Cosmetics Act 1940 and Rules 1945 in order to request approval from the licencing authority (DCGI) in order to manufacture or import a new medicine. Conduct clinical trials in compliance with the regulations outlined in Schedule Y to show its efficacy and safety in the Indian population and submit the report of such clinical trials in the designated format.[43]

According to Rule-122A of the Drug and Cosmetics Act, new medications that have been licenced and used for a number of years in other nations are exempt from the requirement for clinical studies. The Drugs and Cosmetics Act 1940 and Rules 1945's Schedule Y states in section 2.4 (a) that all phases of clinical trials are required for drug compounds identified in India.

According to Section 2.4 (b) of Schedule Y of the Drugs and Cosmetics Act 1940 and Rules 1945, applicants for drug substances discovered in nations other than India must submit data from those nations, and the licencing authority may require that they replicate all of the studies or grant him permission to move on to Phase III clinical trials.

Before the drug product may be licenced for import or production of a new medicine by the applicant by Central Drugs Standard Control Organization (CDSCO), it must first demonstrate its safety and effectiveness for use in humans. The information necessary for approving an application to import or produce a novel medicine for commercialization is described in the regulations under the Drugs and Cosmetics Act of 1940 and its rules 1945, 122A, 122B, and 122D, as well as Appendix I, IA, and VI of Schedule Y.

The Drugs and Cosmetics Act has been updated to incorporate definitions for Phase I–IV studies as well as clearer roles for sponsors and investigators. In 2006, there were two more categories created for the clinical trials. Clinical trials can be carried out in other markets with reliable and established regulatory systems under one category, but the remaining ones come under a different category under the first category.

The DCGI shall receive an application for the conduct of clinical trials in India together with the data of chemistry, manufacturing, control, and animal research. Documents pertaining to informed consent, investigator's brochures, and the trial protocol's date should all be provided.

The ethical committee must get a copy of the application, and clinical trials can only be carried out with DCGI and ethical committee permission.

Phase I clinical studies are carried out on healthy human volunteers in order to control the maximum tolerable dosage in people and adverse responses. Phase II studies with 10–12 patients at each dosage level are conducted to identify the therapeutic applications and optimal dose ranges. Confirmatory studies (Phase III) are carried out to gather information about the drug's effectiveness and safety in around 100 patients (in 3–4 centres) in order to verify efficacy and safety claims. If the new therapeutic ingredient is not already on the market in another nation, phase III trials should be carried out on at least 500 patients spread out over 10–15 centres.[44,45]

Phase IV trials are those conducted after the NDA has been approved, when a company may distribute and promote the product, and during which new applications, populations, long-term impacts, etc. are investigated. The Common Technical Document (CTD) guideline has been created for the United States, European Union, Canada, Japan, and other nations through the International Conference on Harmonization (ICH) process.

The CTD format is used in the majority of nations. So, in order to comply with technical standards for registration of pharmaceutical goods for human use, CDSCO has also decided to adopt CTD format.

Stages of approval

- Submission of Clinical Trial application for evaluating safety and efficacy.
- Requirements for authorization of new drugs approval.
- Post approval changes in biological products: quality, safety, and efficacy documents.
- Preparation of the quality information for drug submission for new drug approval.



Drug Approval Process in India.[44,45,46,47,48]

The procedure for approving drugs differs depending on the nation. In certain nations, the FDA is the only organisation in charge of drug regulation and is in charge of all regulatory tasks, including the approval of new pharmaceuticals, granting manufacturing licences, and inspecting manufacturing facilities. However, in certain nations, such as India, not all regulatory activities are carried out by a single regulatory entity; instead, centralised and state bodies share this role. Some nations, like the USA, have two review processes: a regular review process and an accelerated review process, while others, like India, only have one. The format for the demonstration of the dossier submitted for medication approval is likewise different. It is required in several nations, including the USA, EU, Canada, and Japan, that the dossier only be given in eCTD format.[46,47,48]

Table 2: Manufacturing and control requirements.

Requirements	US	EU	India
Number of batches	1	3	1
Packaging	A minimum of 1,00,0000	Not required	Required
Process validation	Not required at the time of submission	Required	Required
Batch size	1 pilot scale or minimum of 1 lakh unit whichever is higher	2 pilot scales plus 1 lab batch or minimum of 1 lakh units whichever is higher	Pilot scale batch

DISCUSSION

Each country has its own process for licencing medications. The FDA oversees all regulatory activities, including the licencing of new drugs, the awarding of manufacturing licences, and the inspection of production facilities, and is the only organisation in certain countries responsible for drug regulation. However, other countries, like India, do not have a single regulatory body that is responsible for all regulatory actions; instead, state and national government agencies share this responsibility. While other countries, like India, only have one review procedure, some, like the USA, have both a standard review process and an accelerated review process. The presentation of the dossier submitted for drug approval also has a varied format. In a number of countries, including the USA, EU, Canada, and Japan, it is necessary to submit the dossier solely in eCTD format.

Table 3: Principle transformation between US, EU, India.

Requirements	US	EU	India
Agency	One agency USFDA	Multiple agencies • EMEA • CHMP • National health agencies	One agency DCGI
Registration Process	One registration process	Multiple registration process • Centralised (European community) • Decentralised (at least 2 member states) • Mutual recognition (at least 2 member states) • National (1 member state)	One registration process
TSE/BSE study data	Not required	Required	Required
Braille code	Braille code is not required on labelling	Braille code is required on labelling	Braille code is not required on labelling
Post approval changes	Post approval changes in the approved drugs: • Minor • Moderate • Major	Post variation in the approved drugs: • Type IA • Type IB • Type II	Post approved changes: • Major • Moderate
REQUIREMENTS	US	EU	INDIA
Application	ANDA/NDA	MAA	MAA
Department Classification	Required	Not Required	Not Required
Number of copies	3	1	1
Approval Timeline	18 months	12 months	2 - 18 months
Presentation	eCTD and paper	eCTD	Paper

The International Conference on Harmonization (ICH) has made significant strides in harmonisation by recommending a unified interpretation and application of technical criteria. The Common Technical Document (CTD) guideline has been created for the United States, European Union, Canada, Japan, and other nations through the International Conference on Harmonization (ICH) process. India therefore keeps track of the same. The requirement for duplicating work done during the development of new pharmaceuticals will eventually be lessened as a result of this step. As a result, worldwide medication approval procedure harmonisation by ICH or WHO may be started. In the USA and India, there is only one regulatory agency, the USFDA, however in Europe, there are three regulatory agencies: EMEA, CHMP, and NATIONAL HEALTH AGENCY.

CONCLUSION

Since it is the most effective method for bringing new medical advancements to market in a timely manner while maintaining acceptable safety, some in the regulatory affairs field believe the new approach to regulation will eventually be implemented for all healthcare goods. The majority of businesses, whether they are large, multinational pharmaceutical corporations or small, creative biotechnology companies, have specialized regulatory affairs departments. These departments are constantly evolving and are the ones that are least affected by mergers and acquisitions, as well as economic downturns. Some businesses also opt to outsource or delegate regulatory matters to outside service providers due to the shifting resources required to satisfy regulatory standards. The shortening of a product's time to market is essential to its success and that of the company in the highly competitive climate of today. The successful execution of the company's Regulatory Affairs activities is consequently crucial to its financial health. The most difficult drug endorsements in the world are in the USA, Europe, Canada, Japan, and India. Public health protection is the main goal of the

regulations controlling pharmaceuticals in the USA, Europe, Canada, Japan, and India. Public regulatory agencies have the responsibility of ensuring that pharmaceutical firms follow the law. In order to ensure patient safety and well-being, laws exist that mandate that pharmaceuticals be researched, tested, trialed, and manufactured in compliance with the rules.

REFERENCES

1. Woodcock, J., The concept of pharmaceutical quality. American Pharmaceutical Review, 2004; 7(60): 10–15.
2. Lee, D.C., Webb, M.L., Pharmaceutical Analysis, Wiley- Blackwell, 2009; 3.
3. FIP Council, 1999. A joint statement between the international pharmaceutical federation (FIP) and the international federation of pharmaceutical manufacturers associations (IFPMA): ensuring quality and safety of medicinal products to protect the patient, Available at <http://www.fip.org/www/uploads/database_ file.php?id=237&table_id> (accessed 26.10.09).
4. Larson, K., 2004. FDA to prescribe new drug manufacturing standards, Available at <http://www.pharmamanufacturing.com/resource_centers/process_operations/index.html> (accessed 09.08.06).
5. Fraser, H.E., 2005. The metamorphosis of manufacturing; from art to science, IBM business consulting services, Available at <http:// www 935.ibm.com/services/us/imc/pdf/ge510-4034- metamorphosis- of-manufacturing.pdf> (accessed 26.10.09).
6. Dean, D., Bruttin, F., 2001. Productivity and the economics of regulatory compliance in pharmaceutical production, PwC consulting, pharmaceutical sector team, Basel, Switzerland, Available at <http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3841B1_07_PriceWaterhouseCoopers.PDF> (accessed 26.10.09).
7. International regulatory affair updates [online] 2005. Available from http://www.iraup.com/abount.php
8. "Douglas J Pisano and David S. Mantus" 'Text book of FDA Regulatory Affairs A guide for prescription Drugs, Medical Devices, and Biologics'. 2nd edition, August 2008.
9. Topra brough by dimension associates [online] Available from http://www.topra.org/careers/what-regulatory-affairs.
10. Science career brough by American association [online] 2011. Available at https://sciencecareers.sciencemag.org/career_magazine/previous_issues/articles/1999_12_24/noDOI.12079275980051408699.
11. Topra brough by dimension associates [online] available from http://www.topra.org/careers/what-regulatory-affairs.
12. "Training needs in regulatory science for the Biopharmaceutical industry," Naturejobs Biotechnology, 2001; 19(12): 1187-1188.
13. "Careers in Regulatory Affairs from Practitioner to professional," Naturejobs Biotechnology, 2002; 20(4): 409 – 41.
14. Regulatory affairs Management [online]. Available from : https://medind.nic.in/haa/t06/i1/haat07i1p51.
15. Recent advancements [online]. Available from http://en.wikipedia.org/wiki/regulatory_affairs
16. "Careers in Regulatory Affairs from Practitioner to professional," Naturejobs Biotechnology, 2002; 20(4): 409 – 41.
17. Available online: www.centrewatch.com
18. "Training needs in regulatory science for the Biopharmaceutical industry," Naturejobs Biotechnology, 2001; 19(12): 1187-1188.
19. Cutting, Thomas. "How to survive an audit". PM Hut. http://www.pmhut.com/how-to-survive-an-audit. 2008; 2(4): 13-21.
20. FICCI. 2005. White paper on 'clinical Trials in India'.
21. Srivastava Da. Country level report on the pharmaceutical sector in India.' Report commissioned by DFID, UK.
22. Central Drugs Standard Control Organization. (Website: www.cdsco.nic.in)
23. https://www.medindia.net/indian_health_act/drugs-and-cosmetic-act-1940-introduction.htm
24. www.vakilno1.com/bareacts/drugsandcosmeticact/drugsandcosmeticsact.htm
25. https://www.dancewithshadows.com/pillscribe/cgmp-regulations-in-india-to-be-diluted/
26. https://www.prescriptiondrug-info.com/topics/drug-and-cosmetic-act/
27. N.K. Jain, Pharmaceutical product development" edition 3rd, C.B.S publishers
28. P.P. Sharma "how to practice GMPs" 5th edition, Vandana publication Pvt. Ltd Delhi
29. WHO expert committee on specifications for pharmaceutical preparations. Thirty seventh report. Geneva, World Health Organization, 2003 (WHO technical report Series, no. 908)
30. Guide to good storage practices for pharmaceuticals. WHO expert committee on specifications for pharmaceutical preparations. Thirty seventh report. Geneva, World Health Organization, 2003 (WHO technical report Series, no. 908, Annex 9).
31. WHO expert committee on specifications for pharmaceutical preparations. Thirty eighth report. Geneva, World Health Organization, 2004.
32. Good trade and distribution practices for pharmaceutical starting materials. WHO expert committee on specifications for pharmaceutical preparations. Thirty eighth report. Geneva, World Health Organization, 2004. (WHO technical report series, No. 917, annex 2).
33. Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 1. Geneva, World Health Organization, 1997.
34. Quality Assurance of Pharmaceuticals. A

compendium of guidelines and related materials. Good manufacturing practices and inspection, volume 2 (Updated version). Geneva, World Health Organization, 2004.
35. Marketing Authorization of Pharmaceutical Products with special Reference to Multisource (generic) products – A manual for a Drug Regulatory Authority. Geneva, World Health Organization, 1999. (Regulatory support series, No. 5, WHO/ DMP/ RGS/ 98.5).
36. A model quality assurance system for prequalification, procurement, storage and distribution of pharmaceutical products. Geneva, World Health Organization, 2003. (Unpublished draft)
37. Managing drug supply. The selection, procurement, distribution, and use of pharmaceuticals. Management sciences for health in collaboration with world health organization. 2nd Ed. Connecticut, USA. Kumarian Press, Inc., 1997.
38. Principle and guidelines of good manufacturing practice for medicinal products for Human use. Commission Directive 2003 794/356/EEC, 13 June 1991. European Agency for Evaluation of Medicinal Products.
39. Guidance Document: Good manufacturing practice for medicine in South Africa. Medicines control council, South Africa, 2003.
40. Guide to good manufacturing Practices for Medicinal products. Pharmaceutical Inspection convention, Pharmaceutical Inspection Co-operation Scheme, July 2004.
41. Guide to good manufacturing Practices for Medicinal products. Pharmaceutical Inspection convention, Pharmaceutical Inspection Co-operation Scheme, July 2004.
42. Regulatory requirements. Timeline for approval [Internet]. 2005 [Cited 2018 Feb 02]. Available from: www.clinpage.com/article/indias_regulation_timeline/C9.
43. Technical Guidance on Development of In vitro Companion Diagnostics and Corresponding therapeutic Products [Internet]. PMDA; 2013 Dec 26 [Cited 2018 Jan 10]. Available from: https://www.pmda.go.jp/files/000153149.pdf
44. Vishal Gupta N, Mohan Reddy C, Pradeep Reddy K, R Ajay Kulkarni, Shivakumar HG. Process of Approval of New Drug in India with Emphasis on Clinical Trials. International Journal of Pharmaceutical Sciences Review and Research. 2012; 13(2):17-23.
45. Honorio S. Phases of drug development; Good practices in clinical research [Internet]. [cited 2018 May 26]. Available from: http://www.hstelearning.mit.edu.
46. Ravinder RB, Suresh N. Regulatory stages for New Drug approvals [Internet]. [cited 2018 Jan 07]. Available from: https://www.observerindia.com/cms/export/orfonline/modules/occasionalpaper/attachments/Drug_Discovery_Book_1260179432814.pdf
47. Lachman L, Liberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Varghese Publishing House; 1987.
48. The drug development and approval process Overview of the process [Internet]. 2011 [cited 2018 Mar 03]. Available from: http://www.mhsource.com/resource/process.html.